Background: Ovarian cancer is one of the malignancies in women, although it is not contagious, the cases continue to increase. Most ovarian cancers are diagnosed at an advanced stage (stage IIIC or IV). Patients with ovarian cancer can reduce their quality of life, especially at an advanced stage. The quality of life of patients is not only part of the natural history of ovarian cancer, but is also related to the therapy they receive. Especially the administration of chemotherapy or cytostatic drugs.
Methods: This is a report of two cases of the advanced stage of ovarian cancer which were treated in the gynecological oncology room at Sanglah Hospital, Denpasar. The decrease in quality of life in patients with ovarian cancer is illustrated in the case.
Results and Discussion: In the first case, a woman, aged 20 years, complained of abdominal pain and difficulty eating with a history of ovarian cancer. Patients diagnosed with axis 3 with Ovarian Ca post SOD, multiple nodules in the right lung due to metastases, post taping ascites, anemia, and hypoalbuminemia. Patients also experience hypovolemic shock, melena, etc. suspension. SRMD dd/ erosive gastritis. In the second case, a female patient, aged 32 years, was admitted on the 7th day due to abdominal pain, difficulty urinating with a history of ovarian cancer. Patients diagnosed with axis 3 with Ca Ovarian advanced stage, post-SOS, suspected metastases to the left pelvic sidewall, urinary retention after open cystostomy, mild anemia, pain-related neoplasms. Both patients conducted an assessment of the quality of life using the EORTC QLQ-C30 questionnaire. The majority of patients answered the number 4 for each question, which means that the patient is very difficult to carry out basic activities and functions of life. Patients must also be assisted for all activities. Patients choose the number 1 for the quality of health and quality of life which means very bad in this 1 week.
Summary: The quality of life of two cases of advanced-stage ovarian cancer treated in the gynecological oncology room at Sanglah Hospital, Denpasar was poor. It is associated with pain, difficulty performing activities, and basic life functions.
Feeney L, Harley IJ, McCluggage WG, Mullan PB, Beirne JP. Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes. World J Clin Oncol. 2020; 11(11): 868-889.
Trihandini I., Nurrika D. Ovarium Epithelial di Rumah Sakit Kanker Dharmais Jakarta Five-Year Survival Analysis of Epithelial Ovarian Cancer Patients of Dharmais Cancer Hospital Jakarta. J Kesehat Masy Nas. 2010; 5(3): 139–44.
Ahyar I, Rachman I, Kusumanto A. Regimen Paclitaxel dan Carboplatin dengan Regimen Cyclophospamide, Adriamicyn dan Cisplatin. J Kesehat Reproduksi. 2017; 4(1): 1–10. Indonesian.
Greimel E, Kristensen GB, Burg MEL, Coronado P, Rustin G, Sanchez A, et al. Gynecologic Oncology Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neoadjuvant chemotherapy. Gynecol Oncol. 2013; 131(2): 437–44.
Nersesian S, Glazebrook H, Toulany J, Grantham SR, Boudreau JE. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. Front Immunol. 2019; 10: 1782.
Teng FF, Kalloger SE, Brotto L, Mcalpine JN. Determinants of Quality of Life in Ovarian Cancer Survivors : A Pilot Study. J Obstet Gynaecol Canada. 2014; 36(8): 708–15.
Gonçalves V. Quality of Life in Ovarian Cancer Treatment and Survivorship. In: A CLinical and Translational Update. 2013: 27–44.
Domenici L, Palaia I, Giorgini M, Piscitelli V, Tomao F, Marchetti M, et al. Sexual Health and Quality of Life Assessment among Ovarian Cancer Patients during Chemotherapy. Oncology. 2016; 91: 205–10.
This work is licensed under a Creative Commons Attribution 4.0 International License.